ATyr Pharma Rally Continues On Positive Data From Clinical Trial Of Pulmonary Sarcoidosis

Shares of aTyr Pharma Inc. (LIFE) continued its rally on Tuesday, gaining nearly 30% in the morning trade, on top of the 50% increase recorded on Monday's trading.

The clinical-stage biotherapeutics company's stock growth was positively impacted by the positive data from a phase 1b/2a clinical trial demonstrating consistent dose response of ATYR1923 in pulmonary sarcoidosis.

LIFE is currently trading at $11.82, up $2.67 or 29.18%, on the Nasdaq. The stock had opened at $12.31, after closing previous day's trading at $9.15. The stock has traded between $2.93 to $12.97 per share in the past 52-week period. The stock's value has more than tripled in that time frame.

According to the company, ATYR1923 was safe and well-tolerated at all doses with no drug-related serious adverse events or signal of immunogenicity.

Pulmonary sarcoidosis is an inflammatory disease characterized by the formulation of granulomas, clumps of inflammatory cells, in one or more organs of the body. Approximately 200,000 Americans live with pulmonary sarcoidosis.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Pharma Stocks by Subscribing to RTT Biotech Investor.
Follow RTT